GLP-1 Weight-Loss Drug Users Report Higher Rates of Hair and Nail Issues, Study Finds
New research presented at a European dermatology congress suggests a link between GLP-1 medications and adverse nail and hair conditions.
Individuals taking glucagon-like peptide-1 (GLP-1) medications for weight loss or diabetes management are experiencing nail detachment and hair loss at significantly higher rates than those not using the drugs, according to research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna, Austria.
The findings, based on two studies evaluating 575 GLP-1 users and 1,329 non-users with type 2 diabetes, obesity, or both, indicate a notable difference in the incidence of dermatological issues.
Nail Health Concerns
In the study focused on nail health, 39% of GLP-1 users reported nail detachment, compared to 9% of the control group. Nail discoloration affected 46% of medication users versus 17% of non-users. Overall, two-thirds of GLP-1 users (66%) reported at least one nail disorder, compared to 53% of the control group.
Even when accounting for weight loss, participants on GLP-1s were still more likely to experience these nail problems. After adjusting for pre-existing dermatological conditions and nutritional deficiencies, nail detachment and discoloration remained two to three times more frequent among the GLP-1 group.
Dr. Charles Taïeb, a clinical dermatologist at Necker University Hospital in Paris and a study author, noted that while nail changes associated with GLP-1 therapies have been anecdotal, the findings show a clear association. However, he cautioned that not all changes observed during treatment are necessarily caused by the medication itself.
Hair and Scalp Issues
The second study examined hair and scalp conditions. Approximately 50% of GLP-1 users reported unusual hair loss compared to 34% of the control group. After starting treatment, 26% of GLP-1 users reported hair loss or thinning, compared to 12% of those not taking the drugs. Furthermore, a loss of hair volume was reported by 42% of GLP-1 users versus 19% of non-users.
Scalp redness was reported about three times as frequently in GLP-1 users. The study authors observed that hair loss among users was often accompanied by inflammatory scalp symptoms, such as itching, scaling, or redness. Dr. Bruno Halioua, another study author and Paris dermatologist, suggested this points to an inflammatory component beyond the typical shedding seen with rapid weight loss, which may be treatable.
Limitations and Next Steps
The researchers emphasized that both studies relied on self-reported data and were cross-sectional, meaning they cannot definitively prove causation. Approximately half of the GLP-1 users surveyed had experienced nail issues before starting treatment. The research team plans further studies to investigate the timing, causes, and potential resolution of these symptoms over time.
Halioua advised patients experiencing these symptoms to consult a physician rather than discontinuing their medication, as the changes are typically not severe enough to warrant stopping treatment. The studies received institutional support from DUCRAY Laboratories, a division of the Pierre Fabre Group.